A significant disparity in survival outcomes has been identified between bladder cancer patients with color vision deficiencies and those with unimpaired color perception, according to groundbreaking research from Stanford Medicine and its collaborators. This study, drawing upon an extensive analysis of millions of electronic health records, suggests that the inability to discern subtle color changes, particularly red hues, may lead to delayed diagnosis of a critical early warning sign for bladder cancer, thereby increasing mortality risk. The findings underscore a previously underappreciated factor influencing cancer detection and patient prognosis, prompting calls for increased awareness among both healthcare professionals and individuals with colorblindness.
The research team leveraged the TriNetX platform, a vast repository of de-identified patient data encompassing approximately 275 million records globally, to identify individuals possessing the less common co-occurrence of color vision deficiency and bladder cancer. By meticulously cross-referencing diagnostic codes within this immense dataset, scientists were able to isolate specific patient cohorts. The study’s senior author, Dr. Ehsan Rahimy, an adjunct clinical associate professor of ophthalmology at Stanford, emphasized the analytical power of such a large-scale database, likening the process to "casting a net in an ocean’s worth of data" to capture rare combinations of conditions. From an initial pool of around 100 million U.S. patient records, researchers successfully identified 135 individuals diagnosed with both colorblindness and bladder cancer. To ensure robust comparative analysis, a meticulously matched control group was established for each identified patient, consisting of individuals with bladder cancer and similar demographic and health profiles but without color vision deficiency.
The results of this extensive data mining were stark: bladder cancer patients who also had colorblindness exhibited a notably poorer survival rate. Over a twenty-year period, the aggregated mortality risk from all causes was found to be a staggering 52% higher in the group with color vision deficiency compared to their counterparts with normal vision. This elevated risk aligns with the researchers’ initial hypothesis, which was informed by earlier, smaller-scale studies and anecdotal observations. The fundamental premise is that the primary visual cue for bladder cancer – hematuria, or blood in the urine – may go unnoticed by individuals with colorblindness, particularly those with red-green vision deficits, which are the most prevalent forms of color vision deficiency.
Colorblindness, clinically termed color vision deficiency, affects a substantial portion of the population, with approximately one in twelve men and one in two hundred women experiencing some degree of impairment. While often presenting challenges in everyday life, such as distinguishing traffic signals, coordinating attire, or assessing the doneness of cooked meats, its implications for serious health conditions have historically been less understood. Bladder cancer, conversely, disproportionately affects men, who are diagnosed with the disease approximately four times more frequently than women. Projections indicated that in 2025, an estimated 85,000 individuals in the United States would receive a bladder cancer diagnosis, highlighting the significant public health burden of this malignancy.
Prior investigations had indeed hinted at a potential link between colorblindness and delayed diagnoses of diseases where visual cues play a crucial role. Studies involving colorectal cancer and bladder cancer had suggested that individuals with impaired color perception might be diagnosed at later, more advanced stages. A 2009 study, for instance, observed that men with bladder cancer and color vision deficiency were more likely to be diagnosed with more invasive forms of the disease than their sighted peers. Further experimental evidence came from a 2001 study where participants were asked to identify the presence of blood in various bodily fluid samples. While individuals with normal vision correctly identified blood-containing samples with 99% accuracy, those with colorblindness achieved only a 70% accuracy rate. These precursors provided the impetus for Dr. Rahimy and his team to conduct a more comprehensive investigation into the survival implications of this visual impairment in the context of cancer.
Interestingly, the study did not find a similar statistically significant survival difference when examining patients with colorectal cancer and colorblindness. This divergence in outcomes between the two cancer types is attributed to the differing symptomatic presentations and diagnostic pathways. Dr. Rahimy pointed out that blood in the stool, a potential indicator of colorectal cancer, is not typically the most prominent or earliest symptom reported by patients. Instead, abdominal pain and alterations in bowel habits are more frequently the initial complaints, occurring in nearly two-thirds and over half of colorectal cancer patients, respectively. In stark contrast, a significant majority of bladder cancer patients, estimated between 80% and 90%, first notice blood in their urine without experiencing any accompanying pain. Furthermore, the widespread adoption of routine colorectal cancer screening protocols, recommended for most individuals between the ages of 45 and 75, reduces the reliance on self-observed symptoms like blood in stool as the primary detection mechanism. The heightened public awareness and emphasis on early detection for colorectal cancer further contribute to this difference in diagnostic timelines.
The researchers also acknowledge that the observed mortality difference in bladder cancer patients with colorblindness might even be an underestimation. The study’s reliance on standard International Classification of Diseases, Tenth Revision (ICD-10) diagnostic codes, while comprehensive, has inherent limitations. A significant number of individuals with color vision deficiency may never receive a formal diagnosis, particularly if their impairment does not significantly impede their daily functioning or if they lack other associated vision issues. Consequently, these individuals would be misclassified as having normal vision within the electronic health record system, thus potentially masking the true extent of the problem. Dr. Rahimy noted that many affected individuals may be unaware of their condition, functioning perfectly well in most aspects of life.
The implications of these findings extend beyond mere statistical correlation, urging a re-evaluation of standard diagnostic practices and patient education strategies. The study has already sparked important dialogues among medical specialists, including urologists and gastroenterologists, many of whom had not previously considered colorblindness as a factor influencing cancer diagnosis. Some clinicians have expressed an intention to incorporate questions about color vision status into their patient screening questionnaires. Dr. Rahimy articulated his hope that the study would foster a broader awareness, not only among patients but also among healthcare providers who interact with individuals experiencing color vision deficiencies.
For individuals with colorblindness, the research underscores the critical importance of adhering to regular health checkups and being proactive about monitoring for potential health issues. Medical professionals generally recommend annual physical examinations that include a urine test. However, given the findings, individuals with color vision deficiency might benefit from enlisting the support of a partner or family member to help monitor for subtle changes, such as the presence of blood in their urine. Dr. Rahimy suggested that if one is unsure about detecting color-related changes, seeking assistance from a cohabitant to periodically check urine samples for any signs of blood could be a prudent measure to ensure early detection. Further research is warranted to delve deeper into the nuances of how color vision deficiency impacts disease detection across various medical conditions, paving the way for more inclusive and effective healthcare strategies. The study received financial support from the National Institutes of Health and Research to Prevent Blindness, Inc., with contributions from a researcher at Beaumont Health.
About the Author
